www.fdanews.com/articles/85244-spectrum-pharmaceuticals-announces-filing-of-thirteenth-anda-for-an-injectable-drug-with-the-fda
SPECTRUM PHARMACEUTICALS ANNOUNCES FILING OF THIRTEENTH ANDA, FOR AN INJECTABLE DRUG, WITH THE FDA
March 13, 2006
Spectrum Pharmaceuticals, Inc. announced that it has filed its thirteenth Abbreviated New
Drug Application (ANDA), which is for an injectable drug, with the U.S. Food and
Drug Administration (FDA). Spectrum Pharmaceuticals currently has nine other ANDAs
that are under review at the FDA, including an ANDA with Paragraph IV certification
for sumatriptan succinate injection, the generic form of GlaxoSmithKline's Imitrex(R)
injection.
Finanzen.net